AI lung cancer screening software is rapidly entering clinical practice to assist radiologists with early detection. These tools aim to streamline the identification and management of pulmonary nodules. However, a recent analysis of sixteen CE-marked products highlights significant variability in their capabilities. While most tools excel at basic detection, they often fall short in comprehensive clinical management tasks.
Optimizing AI Lung Cancer Screening
Current commercial products primarily focus on detecting and measuring solid and subsolid nodules. Furthermore, most available tools support growth assessment and malignancy risk estimation. These features align with core needs in radiology departments. Consequently, many doctors find these tools helpful for reducing the risk of human error during routine scans. Additionally, some products provide structured malignancy risk scores like PanCan. However, clinicians must note that none of the surveyed products support the management of cystic or endobronchial lesions. This limitation remains a critical gap in fully automated screening workflows.
Clinical Evidence and Guideline Alignment
Despite the proliferation of these tools, their alignment with international guidelines remains inconsistent. Specifically, no commercial product achieved high task coverage for Lung-RADS 2022 or ESTI recommendations. Therefore, radiologists must remain vigilant when using AI for structured management decisions. Moreover, the majority of peer-reviewed evidence clusters at lower efficacy levels. Most studies focus strictly on diagnostic accuracy rather than long-term patient outcomes. Similarly, prospective trials represent only a small fraction of the published research. Thus, clinicians should implement these AI solutions with cautious monitoring and clinical oversight. Meanwhile, studies in diverse settings like India highlight the potential for AI to improve screening accessibility in resource-limited areas.
Frequently Asked Questions
Q1: Can AI tools detect all types of pulmonary nodules?
Most commercial AI products currently focus on solid and subsolid nodules but lack support for cystic or endobronchial lesions.
Q2: How well does AI align with Lung-RADS 2022?
Recent evaluations show that no commercial product currently provides high task coverage specifically for the Lung-RADS 2022 management recommendations.
Q3: What is the level of evidence for most commercial AI products?
The majority of evidence is centered on diagnostic accuracy, with very few prospective studies or reports on long-term patient outcomes.
References
- Antonissen N et al. Commercial AI for CT lung cancer screening: product capabilities, coverage of nodule management tasks and supporting evidence. Eur Radiol. 2026 May 07. doi: 10.1007/s00330-026-12580-x. PMID: 42098370.
- AstraZeneca. Success in Using AI to Screen Lung Cancer from X-ray Images: The CREATE study. 2025 Apr 23.
- Thorax. Software using artificial intelligence for nodule and cancer detection in CT lung cancer screening: systematic review. 2023 Mar 06.